NMS-1116354(NMS-1116354) - 药物靶点：CDC7 x CDK9_在研适应症：血液肿瘤，实体瘤，多发性骨髓瘤_专利_临床

概要

基本信息

药物类型

小分子化药

别名

+ [1]

靶点

CDC7 x CDK9

作用机制

CDC7抑制剂(细胞分裂周期7相关蛋白激酶抑制剂)、CDK9抑制剂(细胞周期蛋白依赖性激酶9抑制剂)

治疗领域

肿瘤血液及淋巴系统疾病免疫系统疾病+ [1]

在研适应症

血液肿瘤实体瘤多发性骨髓瘤

非在研适应症

晚期恶性实体瘤

原研机构

Nerviano Medical Sciences S.r.l

在研机构

Nerviano Medical Sciences S.r.l

National University of Ireland

非在研机构

Nerviano Medical Sciences Group SRL

最高研发阶段临床1期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

关联

2

项与 NMS-1116354 相关的临床试验

NCT01092052 / Terminated临床1期

A Phase I Dose-Escalation Study of NMS-1116354 in Adult Patients With Advanced/Metastatic Solid Tumors

The purpose of this study is to evaluate the safety profile of NMS-1116354, a CDC7 kinase inhibitor, in adult patients with advanced/metastatic solid tumors.

开始日期2010-01-01

申办/合作机构

Nerviano Medical Sciences S.r.l

NCT01016327 / Terminated临床1期

A Phase I Dose-Escalation Study of NMS-1116354 in Adult Patients With Advanced Solid Tumors

The purpose of this study is to evaluate the safety profile of NMS-1116354, a CDC7 kinase inhibitor, in adult patients with advanced solid tumors.

开始日期2009-04-01

申办/合作机构

Nerviano Medical Sciences S.r.l

100 项与 NMS-1116354 相关的临床结果

登录后查看更多信息

100 项与 NMS-1116354 相关的转化医学

登录后查看更多信息

100 项与 NMS-1116354 相关的专利（医药）

登录后查看更多信息

27

项与 NMS-1116354 相关的文献（医药）

2022-07-01·Research in Veterinary Science3区 · 农林科学

Homologous recombination technology generated recombinant pseudorabies virus expressing EGFP facilitates to evaluate its susceptibility to different cells and screen antiviral compounds

3区 · 农林科学

Article

作者: Duan, Deyong ; Wang, Aibing ; Tan, Lei ; Song, Chunlian ; Liao, Fan ; Xu, Kaiwen ; Shu, Xianghua ; Yao, Jun ; Yang, Shibiao

Pseudorabies virus (PRV) is considered as an emerging zoonotic pathogen since its isolation from a human case. Meanwhile, the disease caused by PRV infection has led huge economic losses to Chinese pig industry since 2011. In this study, we constructed a recombinant PRV stably expressing the enhanced green fluorescent protein (EGFP) by homologous recombination technology for evaluating its susceptibility to different human cell lines and screening antiviral compounds. Stably expressed EGFP by this designed rPRVHuN-EGFP virus was confirmed in the infected cells, moreover, the growth kinetics of which was similar to that of wild type strain. Importantly, the application of this rPRV allowed us to easily verify its infectivity in all tested human cell lines, although the infection efficiencies were lower than that in PK15 cells. Meanwhile, the antiviral activities of harmine and PHA767491 were also conveniently validated in vitro, as directly reflected by the reduced EGFP signals. These results demonstrate that this recombinant PRV virus should be a useful tool for basic virology researches and antiviral agent screening.

2021-06-01·Transplantation2区 · 医学

Overexpression of the MSK1 Kinase in Patients With Chronic Lung Allograft Dysfunction and Its Confirmed Role in a Murine Model

2区 · 医学

Article

作者: Durand, Eugénie ; Tissot, Adrien ; Villa, Pascal ; Stern, Marc ; Kessler, Romain ; Roux, Antoine ; Tavakoli, Reza ; Israel-Biet, Dominique ; Frossard, Nelly ; Nemska, Simona ; Brouard, Sophie ; Magnan, Antoine ; Reber, Laurent ; Obrecht, Adeline ; Foureau, Aurore ; Daubeuf, François ; Danger, Richard

Background.Chronic lung allograft dysfunction (CLAD) and its obstructive form, the obliterative bronchiolitis (OB), are the main long-term complications related to high mortality rate postlung transplantation. CLAD treatment lacks a significant success in survival. Here, we investigated a new strategy through inhibition of the proinflammatory mitogen- and stress-activated kinase 1 (MSK1) kinase.Methods.MSK1 expression was assessed in a mouse OB model after heterotopic tracheal allotransplantation. Pharmacological inhibition of MSK1 (H89, fasudil, PHA767491) was evaluated in the murine model and in a translational model using human lung primary fibroblasts in proinflammatory conditions. MSK1 expression was graded over time in biopsies from a cohort of CLAD patients.Results.MSK1 mRNA progressively increased during OB (6.4-fold at D21 posttransplantation). Inhibition of MSK1 allowed to counteract the damage to the epithelium (56% restoration for H89), and abolished the recruitment of MHCII+ (94%) and T cells (100%) at the early inflammatory phase of OB. In addition, it markedly decreased the late fibroproliferative obstruction in allografts (48%). MSK1 inhibitors decreased production of IL-6 (whose transcription is under the control of MSK1) released from human lung fibroblasts (96%). Finally, we confirmed occurrence of a 2.9-fold increased MSK1 mRNA expression in lung biopsies in patients at 6 months before CLAD diagnosis as compared to recipients with stable lung function.Conclusions.These findings suggest the overall interest of the MSK1 kinase either as a marker or as a potential therapeutic target in lung dysfunction posttransplantation.

2020-07-01·Journal of Molecular Neuroscience3区 · 医学

Targeting Inflammation, PHA-767491 Shows a Broad Spectrum in Protein Aggregation Diseases

3区 · 医学

Article

作者: Hsieh-Li, Hsiu Mei ; Chang, Ya-Ching ; Lee, Guan-Chiun ; Lee-Chen, Guey-Jen ; Sun, Ying-Chieh ; Huang, Hsin-Yu ; Lin, Chia-Wei ; Huang, Hei-Jen ; Chen, Shu-Ling ; Chung, Yu-Han

Many protein aggregation diseases (PAD) affect the nervous system. Deposits of aggregated disease-specific proteins are found within or around the neuronal cells of neurodegenerative diseases. Although the main protein component is disease-specific, oligomeric aggregates are presumed to be the key agents causing the neurotoxicity. Evidence has shown that protein aggregates cause a chronic inflammatory reaction in the brain, resulting in neurodegeneration. Therefore, strategies targeting anti-inflammation could be beneficial to the therapeutics of PAD. PHA-767491 was originally identified as an inhibitor of CDC7/CDK9 and was found to reduce TDP-43 phosphorylation and prevent neurodegeneration in TDP-43 transgenic animals. We recently identified PHA-767491 as a GSK-3β inhibitor. In this study, we established mouse hippocampal primary culture with tau-hyperphosphorylation through the activation of GSK-3β using Wortmannin and GF109203X. We found that PHA-767491 significantly improved the neurite outgrowth of hippocampal primary neurons against the neurotoxicity induced by GSK-3β. We further showed that PHA-767491 had neuroprotective ability in hippocampal primary culture under oligomeric Aβ treatment. In addition, PHA-767491 attenuated the neuroinflammation in mouse cerebellar slice culture with human TBP-109Q agitation. Further study of SCA17 transgenic mice carrying human TBP-109Q showed that PHA-767491 ameliorated the gait ataxia and the inflammatory response both centrally and peripherally. Our findings suggest that PHA-767491 has a broad spectrum of activity in the treatment of different PAD and that this activity could be based on the anti-inflammation mechanism.

100 项与 NMS-1116354 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
血液肿瘤	临床1期	意大利	Nerviano Medical Sciences S.r.l	2010-04-15
晚期恶性实体瘤	临床1期	美国	Nerviano Medical Sciences S.r.l	2009-04-01
实体瘤	临床1期	法国	Nerviano Medical Sciences Group SRL	-
多发性骨髓瘤	临床前	爱尔兰	National University of Ireland	2009-11-20